Related Experiment Video

Updated: Aug 12, 2026

Cardiac Stress Test Induced by Dobutamine and Monitored by Cardiac Catheterization in Mice
15:45

Cardiac Stress Test Induced by Dobutamine and Monitored by Cardiac Catheterization in Mice

Published on: February 10, 2013

Dobutamine enhances cardiodepressant effects of receptor-mediated coronary endothelial stimulation

J Bartunek1, A M Shah, M Vanderheyden

  • 1Cardiovascular Center, Aalst, Belgium.

Circulation
|January 7, 1997
PubMed

Insights

Beta-adrenergic stimulation with dobutamine enhances the heart-relaxing effects of substance P in patients with heart transplants and cardiomyopathy. This interaction may involve nitric oxide, improving myocardial contractile performance.

Area of Science:

  • Cardiology
  • Pharmacology
  • Physiology

Background:

  • Intracoronary substance P infusion reduces left ventricular pressures by promoting earlier relaxation via paracrine action of endothelial mediators.
  • Beta-adrenergic stimulation also induces earlier left ventricular relaxation.

Purpose of the Study:

  • To investigate the effects of beta-adrenergic stimulation on the myocardial contractile response to intracoronary substance P infusion in humans.

Main Methods:

  • Data collected from 13 heart transplant recipients and 3 patients with dilated cardiomyopathy.
  • Left ventricular pressure recordings obtained during intracoronary substance P infusion.
  • Measurements repeated during concurrent intravenous dobutamine administration.

Main Results:

  • Dobutamine significantly increased the fall in left ventricular end-systolic pressure and peak systolic pressure induced by substance P in both patient groups.
  • The cardiodepressant effect of substance P was enhanced by dobutamine.

Conclusions:

  • Dobutamine potentiates the cardiodepressant effects of substance P on myocardial contractile performance in transplant recipients and cardiomyopathy patients.
  • This enhancement may stem from an interaction between beta-adrenergic stimulation and endothelial mediators like nitric oxide.
Abstract

More Related Videos

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

Surgical Placement of Catheters for Long-term Cardiovascular Exercise Testing in Swine12:37

Surgical Placement of Catheters for Long-term Cardiovascular Exercise Testing in Swine

Published on: February 9, 2016

Related Concept Videos

Adrenergic Agonists: Direct-Acting Agents01:30

Adrenergic Agonists: Direct-Acting Agents

Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...